Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Xenetic Biosciences's Revenue for the
three
months ended in Jun. 2026 was $0.66 Mil. Xenetic Biosciences's average Accounts Receivable for the
three
months ended in Jun. 2026 was $0.00 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Xenetic Biosciences Receivables Turnover Related Terms
Xenetic Biosciences Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Xenetic Biosciences's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBIO vs ADIL, PULM, KAPA: Receivables Turnover Comparison
For the Biotechnology subindustry, Xenetic Biosciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenetic Biosciences Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Xenetic Biosciences's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenetic Biosciences (XBIO) has a Receivables Turnover of 0.00 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Xenetic Biosciences and its competitors. According to the industry distribution chart, Xenetic Biosciences ranks #999999 out of 842 companies in the Biotechnology industry.
Is Xenetic Biosciences' Receivables Turnover too high?
Xenetic Biosciences' current Receivables Turnover is 0.00. Based on the distribution chart, Xenetic Biosciences ranks #999999 out of 842 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xenetic Biosciences has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' Receivables Turnover compare to ADIL and PULM?
According to the Biotechnology industry distribution chart, Xenetic Biosciences ranks #999999 out of 842 companies for Receivables Turnover. This places Xenetic Biosciences in the lower half of its industry. The industry median Receivables Turnover is 5.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Xenetic Biosciences and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xenetic Biosciences's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Xenetic Biosciences (XBIO) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.76, compared to a current price of $3.23 — trading 14.1% below its estimated fair value. The current Receivables Turnover is 0.00. Xenetic Biosciences' overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Xenetic Biosciences (XBIO), the current Receivables Turnover is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xenetic Biosciences (XBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued.
The current stock price of $3.23 is trading 14.1% below its estimated GF Value™ of $3.76.
GuruFocus considers Xenetic Biosciences to be Modestly Undervalued.
Key valuation signals for XBIO:
Receivables Turnover: 0.00
GF Value™: $3.76 vs. price of $3.23 (14.1% below fair value)
No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
84GF Score
Get the complete analysis for XBIO
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBIO has been successfully added to your 
